Evaluating the Uric Acid/Albumin Ratio as a Biomarker for Disease Severity in Acute Myocarditis Patients
Abstract
ABSTRACT
Aim Uric acid/albumin ratio (UAR) has recently emerged as a potential marker for oxidative stress and inflammation, which are key components in the pathophysiology of myocarditis. Therefore, high UAR may reflect increased disease activity and severity in myocarditis patients. In this study, we aimed to evaluate the usability of uric acid/albumin ratio as a biomarker in determining disease severity in patients with acute myocarditis.
Methods The study population was evaluated retrospectively. Laboratory parameters of the patients were examined. We classified the condition as severe myocarditis based on the presence of refractory chest pain, hypotension, detection of pericardial effusion with subsequent increase, a decrease in ejection fraction (EF), and lack of response to medical and symptomatic treatment. The primary outcome was the association between UAR and disease severity.
Results The median age was 43.5 years. The UAR was significantly higher in females (0.10 vs. 0.10, p=0.003). Patients with pericardial effusion had significantly higher UARs (0.137 vs. 0.100, p<0.001), and those requiring intensive therapies such as inotropes, IV steroids, or IVIG also showed elevated UARs.
Conclusion Our study provides evidence supporting the use of UAR as a novel marker for assessing disease severity in acute myocarditis patients. By integrating markers of oxidative stress and nutritional/inflammatory status, UAR offers a comprehensive tool for risk stratification and management in clinical practice
Keywords
Supporting Institution
Yok
Ethical Statement
Konya Necmettin Erbakan Üniversitesi Etik Kurulu'ndan etik kurul onayı aldık. Çalışma için etik kurul onayı üniversite komitesinin 17/05/2024 tarih ve 2024/4975 sayılı toplantısının kararıyla alındı.
Thanks
Çalışmamızı değerlendirdiğiniz ve değerli zamanınızı ayırdığınız için teşekkür ederim. Saygılarımla.
References
- 1. Ammirati E, Moslehi JJ. Diagnosis and Treatment of Acute Myocarditis: A Review. JAMA 2023; 329(13):1098-1113
- 2. Ammirati E, Veronese G, Bottiroli M, Wang DW, Cipriani M, Garascia A, et al. Update on acute myocarditis. Trends Cardiovasc Med 2021; 31(6):370-379
- 3. Lampejo T, Durkin SM, Bhatt N, Guttmann O. Acute myocarditis: aetiology, diagnosis and management. Clin Med (Lond) 2021; 21(5):e505-e510
- 4. Golpour A, Patriki D, Hanson PJ, McManus B, Heidecker B. Epidemiological Impact of Myocarditis. J Clin Med 2021; 10(4)
- 5. Rroku A, Kottwitz J, Heidecker B. Update on myocarditis - what we know so far and where we may be heading. Eur Heart J Acute Cardiovasc Care 2021; 10(4):455-467
- 6. Basso C. Myocarditis. N Engl J Med 2022; 387(16):1488-1500
- 7. Tschope C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol 2021; 18(3):169-193
- 8. Kim HW, Jenista ER, Wendell DC, Azevedo CF, Campbell MJ, Darty SN, et al. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol 2021; 6(10):1196-1201
- 9. Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and Pericarditis After Vaccination for COVID-19. JAMA 2021; 326(12):1210-1212
- 10. Ozgur Y, Akin S, Yilmaz NG, Gucun M, Keskin O. Uric acid albumin ratio as a predictive marker of short-term mortality in patients with acute kidney injury. Clin Exp Emerg Med 2021; 8(2):82-88